Ultragenyx has received FDA accelerated approval for Genglycos™

The first-ever treatment designed to address the underlying genetic cause of Glycogen Storage Disease Type Ia (GSDIa) = an ultra-rare, inherited metabolic disorder affecting approximately 1 in 100,000 live births worldwide (an estimated 1,500-2,500 patients in the U.S ).